ANGPTL3 缺陷与冠心病保护作用
家族性联合低脂血症由 ANGPTL3 失活突变所致。本研究通过家系、人群遗传关联和生物标志物三条证据线,发现完全缺陷者无冠状动脉斑块,杂合携带者冠心病风险降低,低循环 ANGPTL3 水平与心肌梗死风险降低相关。
要点
- 完全 ANGPTL3 缺陷的 3 名个体未见冠状动脉粥样硬化斑块证据。
- 杂合 LOF 突变携带者冠心病风险降低 34%(OR 0.66,95%CI 0.44–0.98,P=0.04)。
- 循环 ANGPTL3 浓度最低三分位者心肌梗死风险降低(校正 OR 0.65,95%CI 0.55–0.77,P<0.001)。
核心结论
- ANGPTL3 缺陷与冠心病保护作用相关。
研究设计与样本
- 研究采用三条证据线:一个包含完全(复合杂合)ANGPTL3 缺陷个体的家系、一项部分(杂合)ANGPTL3 缺陷人群研究,以及心肌梗死患者的生物标志物研究。
- 家系中采用 CT 血管造影评估 3 名完全 ANGPTL3 缺陷个体和 3 名野生型一级亲属的冠状动脉粥样硬化负荷。
- 人群研究中在最多 21,980 名冠心病患者和 158,200 名对照者中检测 ANGPTL3 功能缺失(LOF)突变。
- 生物标志物研究中测量了 1,493 名心肌梗死患者和 3,232 名对照者的循环 ANGPTL3 浓度。
主要发现
- 3 名完全 ANGPTL3 缺陷个体未见冠状动脉粥样硬化斑块证据。
- ANGPTL3 基因测序显示约每 309 人中 1 人为 LOF 突变杂合携带者。
- 与无突变者相比,ANGPTL3 LOF 突变杂合携带者循环甘油三酯降低 17%,低密度脂蛋白胆固醇降低 12%。
- 携带者状态与冠心病风险降低 34% 相关(OR 0.66,95%CI 0.44–0.98,P=0.04)。
- 循环 ANGPTL3 浓度最低三分位者与最高三分位者相比,心肌梗死风险降低(校正 OR 0.65,95%CI 0.55–0.77,P<0.001)。
关键数值与推荐
- LOF 突变定义为无义、移码和剪接位点变异,以及在小鼠模型中导致 ANGPTL3 活性低于野生型 25% 的错义变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown. OBJECTIVES: The study goal was to leverage 3 distinct lines of evidence-a family that included individuals with complete (compound heterozygote) ANGPTL3 deficiency, a population based-study of humans with partial (heterozygote) ANGPTL3 deficiency, and biomarker levels in patients with myocardial infarction (MI)-to test whether ANGPTL3 deficiency is associated with lower risk for CAD. METHODS: We assessed coronary atherosclerotic burden in 3 individuals with complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using computed tomography angiography. In the population, ANGPTL3 loss-of-function (LOF) mutations were ascertained in up to 21,980 people with CAD and 158,200 control subjects. LOF mutations were defined as nonsense, frameshift, and splice-site variants, along with missense variants resulting in <25% of wild-type ANGPTL3 activity in a mouse model. In a biomarker study, circulating ANGPTL3 concentration was measured in 1,493 people who presented with MI and 3,232 control subjects. RESULTS: The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque. ANGPTL3 gene sequencing demonstrated that approximately 1 in 309 people was a heterozygous carrier for an LOF mutation. Compared with those without mutation, heterozygous carriers of ANGPTL3 LOF mutations demonstrated a 17% reduction in circulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol. Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04). Individuals in the lowest tertile of circulating ANGPTL3 concentrations, compared with the highest, had reduced odds of MI (adjusted odds ratio: 0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001). CONCLUSIONS: ANGPTL3 deficiency is associated with protection from CAD.
引用
- Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol. 2017. PMID: 28385496. doi:10.1016/j.jacc.2017.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。